Enes Yeşilbaş

Association between PhenoAge-assessed biological age and survival outcomes in solid tumor patients treated with immune checkpoint inhibitors

Abstract Background Chronological age may influence immune function, but individuals of the same age may differ in biological aging. We evaluated the association between biological age and clinical outcomes in patients with solid tumors treated with immune checkpoint inhibitor mo...

Post-Recurrence Outcomes Associated with a Bevacizumab-Containing First-Recurrence Strategy in Glioblastoma: A Propensity-Weighted Single-Center Cohort Study with Competing-Risk Analysis

Background/Objectives: Bevacizumab is widely used at recurrence in glioblastoma, but comparisons are complicated by multimodal treatment selection and progression assessment. We examined outcomes associated with a bevacizumab-containing first-recurrence strategy and explored the...